

Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Edwards

Phone: 650-351-4730

E-mail:

investor@globalbloodtx.com

Stock Performance

GBT (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price \$26.80

Change (%) ▼ 0.8 (2.90%)

Volume 673,157

52 Week Low \$13.35


Market Cap \$1,170,538,347

Rolling EPS -2.47

PE Ratio 0

Shares Outstanding 43,676,804

Data as of 08/21/17 4:00 p.m. ET



Recent Headlines & Events

08/09/17

Global Blood Therapeutics Announces Participation at

the 2017 Wedbush PacGrow Healthcare Conference

08/07/17

Global Blood Therapeutics Reports Recent Business

Progress and Provides Second Quarter 2017 Financial

Results

07/26/17

Global Blood Therapeutics Announces New

Employment Inducement Grants

There are currently no events scheduled.

SEC I	Filings
-------	---------

Filing Date Form 08/14/17 4 08/14/17 4 08/14/17 4 08/14/17 4

Corporate Governance

Ted W. Love, M.D. Chief Executive Officer

Jeffrey Farrow Chief Financial Officer

Jung E. Choi Chief Business and Strategy Officer

Tricia Suvari Chief Legal Officer

Hing Sham, Ph.D. Senior Vice President, Research

Peter Radovich Vice President, Program Leadership

and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.